FOXO4-DRI vs NMN
A side-by-side research comparison of FOXO4-DRI and NMN across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | NMN |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Nicotinamide Mononucleotide |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Dietary compound (research ongoing) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | NMN is converted to NAD+ via the NAD+ salvage pathway (through NMNAT enzymes). Higher NAD+ supports sirtuin activity, PARP-mediated DNA repair, and mitochondrial energy metabolism. |
| Molecular weight | ~4,500 Da | 334.22 Da |
| Half-life | 12-24 hours (D-amino acid stability) | Short; rapidly taken up and converted to NAD+ |
| Bioavailability | Moderate (SubQ) | Oral absorption reported; sublingual and injectable forms also used |
| Typical dose | 5-10 mg/kg (animal studies) | 250-1000 mg per day |
| Frequency | 3x per week for 3 weeks | Once daily |
| Route | Subcutaneous | Oral (capsule/sublingual) |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
NMN reported benefits
- Raises cellular NAD+ levels
- Supports mitochondrial energy production
- Promotes DNA repair via sirtuins/PARPs
- Studied for metabolic and vascular health
Related comparisons
Research and educational reference only. Not medical advice.